A Study of HS-20094 in Healthy Participants

Inclusion Criteria:

1. Screening weight of male ≥50 kg, female≥45 kg and 19≤BMI≤28
2. Subjects agree to use an effective method of contraception and avoid sperm or eggdonation for the duration of the study and for 6 months following the last dose ofinvestigational product
3. Agree to avoid alcohol, foods and beverages containing xanthine or caffeine (includingchocolate, tea, coffee, cola, etc.) from 48 hours prior to administration to lastvisit, and to avoid strenuous exercise

Exclusion Criteria:

1. Pregnant or lactating women
2. Subjects have a medical history of cardiovascular, respiratory, liver, kidney,digestive tract, mental, neurological, hematology or metabolic abnormalities (e.g.,repeated hypoglycemia for unknown reasons) and are judged not suitable for this studyby the investigator.
3. Subjects with abnormal screening vital signs, physical examination, laboratoryexamination or 12 lead electrocardiogram results with clinical significance
4. Have a history of drug allergy, or known allergies to HS-20094, glucagon-like peptide (GLP)-1 analogs, or glucose-dependent insulinotropic polypeptide (GIP) receptoragonism
5. Received systemic steroid therapy, immunomodulator therapy or chemotherapy in the 3months prior to screening, or are likely to receive these treatments during the studyperiod
6. Have a history of digestive disease (e.g., gastroesophageal reflux disease,gallbladder disease, or chronic enteritis) that may affect gastrointestinal adverseevents assessment or any other gastrointestinal disease (e.g., gastric bypass surgery,pyloric stenosis, etc.) that may affect gastric emptying
7. Have a diet, weight loss treatment or significant lifestyle changes prior to 30 daysof administration